BDBM11995 2-chloro-5-(2,5-dimethyl-1H-pyrrol-1-yl)benzoic acid::Interchim compound 57
SMILES: Cc1ccc(C)n1-c1ccc(Cl)c(c1)C(O)=O
InChI Key: InChIKey=ZKMKAGTWPRBWAK-UHFFFAOYSA-N
Target/Host (Institution) | Ligand | Target/Host Links | Ligand Links | Trg + Lig Links | Ki nM | ΔG° kcal/mole | IC50 nM | Kd nM | EC50/IC50 nM | koff s-1 | kon M-1s-1 | pH | Temp °C |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Anthrax Lethal Factor (LF) (Bacillus anthracis) | BDBM11995 (2-chloro-5-(2,5-dimethyl-1H-pyrrol-1-yl)benzoic ac...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL B.MOAD DrugBank GoogleScholar AffyNet | Purchase PC cid PC sid UniChem Patents Similars | Article PubMed | 5.60E+3 | -7.21 | 6.80E+3 | n/a | n/a | n/a | n/a | 7.2 | 27 |
Montana State University | Assay Description For selected lead compounds from fluorescence-based high-throughput screening, the concentrations of inhibitor that caused 50% inhibition of enzymati... | J Med Chem 49: 5232-44 (2006) Article DOI: 10.1021/jm0605132 BindingDB Entry DOI: 10.7270/Q20C4T19 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tyrosyl-DNA phosphodiesterase 1 (Homo sapiens (Human)) | BDBM11995 (2-chloro-5-(2,5-dimethyl-1H-pyrrol-1-yl)benzoic ac...) | PDB KEGG UniProtKB/SwissProt UniProtKB/TrEMBL B.MOAD antibodypedia GoogleScholar AffyNet | Purchase PC cid PC sid UniChem Patents Similars | Article PubMed | n/a | n/a | 110 | n/a | n/a | n/a | n/a | n/a | n/a |
Siberian Branch of the Russian Academy of Sciences Curated by ChEMBL | Assay Description Inhibition of Tdp1 (unknown origin) | Eur J Med Chem 161: 581-593 (2019) Article DOI: 10.1016/j.ejmech.2018.10.055 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Pyruvate kinase (PKM2) (Homo sapiens (Human)) | BDBM11995 (2-chloro-5-(2,5-dimethyl-1H-pyrrol-1-yl)benzoic ac...) | PDB KEGG UniProtKB/SwissProt UniProtKB/TrEMBL B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | Purchase PC cid PC sid UniChem Patents Similars | US Patent | n/a | n/a | >1.00E+5 | n/a | n/a | n/a | n/a | n/a | n/a |
Beth Israel Deaconess Medical Center, Inc. US Patent | Assay Description Primary screening was performed using PKM2 in the presence of FBP. Compounds were chosen as potential "hits" if the compound demonstrated inhibition ... | US Patent US8877791 (2014) BindingDB Entry DOI: 10.7270/Q2D21WBN | |||||||||||
More data for this Ligand-Target Pair |